The Paragon Report issued an equity research report on Peregrine Pharmaceuticals Inc. (Nasdaq: PPHM) last week saying that shares of the biotechnology firm would continue soaring for the rest of the year. The stock price climbed 46 cents to close at $1.74.
Peregrine Expected To Continue Soaring
July 23, 2012 at 18:15 PM EDT
